Benzinga · Mar 5, 2026
B. Riley Securities Maintains Buy on ClearPoint Neuro, Lowers Price Target to $18
B. Riley Securities analyst Neil Chatterji maintains ClearPoint Neuro (NASDAQ:CLPT) with a Buy and lowers the price target from $28 to $18.
NASDAQ · CLPT
Healthcare · Medical - Devices
$15.39
Up+$0.20 (+1.32%)
Updated Aug 22, 2026, 3:31 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
CLPT closed at $15.39 after 21 trading sessions, up 8.99% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $15.13 | $15.53 | $14.965 | $15.39 | 560.73K |
| Aug 20, 2026 | $15.77 | $16.075 | $15.18 | $15.19 | 398.13K |
| Aug 19, 2026 | $15.40 | $16.08 | $15.395 | $15.96 | 516.78K |
| Aug 18, 2026 | $15.28 | $15.675 | $15.14 | $15.18 | 253.07K |
| Aug 17, 2026 | $15.35 | $15.615 | $15.0301 | $15.50 | 413.73K |
| Aug 14, 2026 | $15.59 | $15.59 | $15.2235 | $15.34 | 299.28K |
| Aug 13, 2026 | $15.11 | $15.49 | $15.11 | $15.42 | 319.24K |
| Aug 12, 2026 | $14.91 | $15.315 | $14.46 | $15.18 | 538.74K |
| Aug 11, 2026 | $14.63 | $14.95 | $14.35 | $14.90 | 712.22K |
| Aug 10, 2026 | $14.27 | $14.70 | $14.26 | $14.57 | 423.69K |
| Aug 7, 2026 | $14.00 | $14.35 | $13.9254 | $14.21 | 520.7K |
| Aug 6, 2026 | $13.03 | $13.46 | $12.9432 | $13.39 | 666.41K |
| Aug 5, 2026 | $13.01 | $13.34 | $12.675 | $13.16 | 627.87K |
| Aug 4, 2026 | $13.02 | $13.3899 | $12.27 | $12.875 | 2.89M |
| Aug 3, 2026 | $14.91 | $15.53 | $14.65 | $15.38 | 747K |
| Jul 31, 2026 | $14.90 | $14.97 | $14.23 | $14.94 | 605.34K |
| Jul 30, 2026 | $14.26 | $14.68 | $14.04 | $14.58 | 438.83K |
| Jul 29, 2026 | $14.41 | $14.88 | $13.825 | $14.14 | 526.23K |
| Jul 28, 2026 | $14.61 | $14.61 | $13.93 | $14.53 | 663.92K |
| Jul 27, 2026 | $14.16 | $14.86 | $14.16 | $14.60 | 324.54K |
| Jul 24, 2026 | $14.61 | $14.675 | $14.10 | $14.12 | 467.36K |
The latest Smart Investors Daily articles mentioning CLPT.
CLPT research
Company profile and research snapshot.
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 18, 2026 | B. Riley Securities | Buy | — |
| Mar 18, 2026 | B. Riley Securities | Buy | — |
| Mar 5, 2026 | B. Riley Securities | Buy | — |
| Aug 1, 2025 | Stifel | Buy | — |
| Apr 1, 2025 | Stifel | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 5, 2026
B. Riley Securities analyst Neil Chatterji maintains ClearPoint Neuro (NASDAQ:CLPT) with a Buy and lowers the price target from $28 to $18.
Yahoo · Jan 27, 2026
ClearPoint secures EU MDR certification for ClearPoint Navigation Software 3.0.2, expanding precision-guided surgery access across MRI suites and operating rooms.
SeekingAlpha · Jan 27, 2026
ClearPoint Neuro outlook for 2026: IRRAS, PRISM 1.5T clearance & new CRO facility could drive growth. Learn more about CLPT stock here.
Yahoo · Jan 22, 2026
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has ...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning CLPT.